Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN
Status:
Unknown status
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Radiotherapy alone is generally the only treatment in old patients with SCCHN. No evidence
indicates combination with EGFR Target therapy can bring benefit for the patients. Senile
Society is coming in China, the mean age in Beijing reaches 80 years old. A valuable
treatment with efficacy and safety is needed for senile patient with SCCHN. The purpose of
the study "Prospective, Randomized, Controlled, Phase II Multiple Centered Clinical Trial of
Nimotuzumab Combined with Radiotherapy for Senile Locally Advanced SCCHN" was sponsored to
evaluate the efficacy and safety for Nimotuzumab Combined with Radiotherapy in Senile SCCHN
patients.